News | PET Imaging | July 16, 2020

Molecular Imaging Identifies Link Between Heart and Kidney Inflammation After Heart Attack

Novel imaging agent provides foundation to inform treatment strategies

Novel imaging agent provides foundation to inform treatment strategies

Getty Images

July 16, 2020 — Whole body positron emission tomography (PET) has, for the first time, illustrated the existence of inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction, or heart attack. According to research presented at the Society of Nuclear Medicine and Molecular Imaging's 2020 Annual Meeting, the identification of a systemic inflammatory response to myocardial infarction has the potential to assist physicians in identifying patients most at risk of disease progression and most likely to respond to therapy.

Patients with acute myocardial infarction often develop impaired kidney function, thought to be mediated by the activation and mobilization of immune cells, or inflammation. While inflammation is necessary for effective healing, uncontrolled inflammatory cell activity can be detrimental for both the heart and the kidneys. To further understand the mechanics of this bidirectional interaction, researchers conducted a preclinical analysis of a novel imaging agent that targets inflammatory cells after myocardial infarction.

Using serial whole-body CXCR4-targeted 68Ga-pentixafor PET, researchers imaged 65 mice after surgically-induced myocardial infarction or sham surgery at one day, three days, seven days and six weeks. Tracer retention was determined in the kidneys and compared to infarct signal and cardiac function, as measured independently by magnetic resonance.

Cardiac CXCR4 signal was significantly elevated on the first day of imaging and returned to sham level after seven days. Renal CXCR4 signal was unchanged on the first day of imaging, but was reduced after seven days as compared to sham levels. Cardiac and renal signal were directly correlated, suggesting an inflammatory link between the heart and the kidneys. Ex-vivo autoradiography confirmed a significant correlation between tracer retention in the myocardial infarction region and the kidneys.

"This study provides a foundation for simultaneous examination of heart and kidneys after myocardial infarction by using molecular imaging," noted Rudolf Werner, M.D., Ph.D., resident in the department of nuclear medicine at Hannover Medical School in Hannover, Germany. "It provides an impetus for the pursuit of systems-based multi-organ imaging to investigate systemic response to focal injury."

He continued, "Assessment of inflammation after myocardial infarction is beginning to be evaluated in clinical populations. With the growth of long-bore cameras with larger fields of view, the concept of multi-organ imaging will expand substantially in the next years.

In the future, nuclear medicine techniques may identify the optimal patient and time point for anti-inflammatory therapy, and identify the added risk to off-target organs after primary injury."

For more information: www.snmmi.org

 

Related SNMMI20 Content:

SNMMI Channel

PSMA PET/CT Can Change Management in Recurrent Prostate Cancer

Total-body Dynamic PET Successfully Detects Metastatic Cancer

New PET Radiotracer Proven Safe in Imaging Malignant Brain Tumors

Targeted Radionuclide Therapy Enhances Prostate Cancer Response to Immunotherapies

New PET/MRI Approach Pinpoints Chronic Pain Location, Alters Management

 

Related Content

After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by

After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by N. Galldiks et al., Research Center Juelich, Juelich, Germany.

News | PET Imaging | May 05, 2021
May 5, 2021 — For patients with brain metastases, amino acid ...
The emergence of #therapeutic #radiopharmaceuticals and its adoption in #cancer care provide one more weapon in combating cancer

Getty Images

Feature | Radiation Oncology | May 04, 2021 | By Vinay Shivaprasad
The term nuclear medicine is associated with the diag
The Women’s Heart Attack Research Program (HARP) study shows combining OCT and cardiac MRI can help detect the underlying cause of heart attacks in women who did not have blocked arteries.

The Women’s Heart Attack Research Program (HARP) study shows combining OCT and cardiac MRI can help detect the underlying cause of heart attacks in women who did not have blocked arteries.

News | Cardiac Imaging | April 30, 2021
April 30, 2021 — In almost 10 percent of...
Spectral DLR enables improved assessment of lumen stenosis in the presence of calcified plaque. Interactive monochromatic image display enables improved opacification of the injected contrast with low keV images and reduced calcium blooming artifacts with high keV images

Spectral DLR enables improved assessment of lumen stenosis in the presence of calcified plaque. Interactive monochromatic image display enables improved opacification of the injected contrast with low keV images and reduced calcium blooming artifacts with high keV images. The range of monochromatic energy levels (35-135 keV) can be visualized in real time through an image slider in the application that can be integrated in to a PACS.

News | Cardiac Imaging | April 21, 2021
April 21, 2021 — Meeting the growing cardiovascular needs of healthcare providers today, ...
olecular Targeting Technologies, Inc. (MTTI) announced the issuance of United States Patent # 10,953,113. The patent claims a quick (5 min), easy and quantitative conversion of commercially available 18F-deoxyglucose (18F-FDG) to 18F-Fluroglucaric acid (18F-FGA).

Getty Images

News | PET Imaging | April 19, 2021
April 19, 2021 — Molecular Targeting Technologies, Inc.
The inflamed joints of a #rheumatoid #arthritis patient are clearly visible in the #PET images with the novel 68Ga-DOTA-Siglec-9 #radiopharmaceutical. Image courtesy of Anne Roivainen

The inflamed joints of a rheumatoid arthritis patient are clearly visible in the PET images with the novel 68Ga-DOTA-Siglec-9 radiopharmaceutical. Image courtesy of Anne Roivainen

News | PET Imaging | April 19, 2021
April 19, 2021 — The preliminary...
#NorthStar Medical #Radioisotopes, LLC, a global innovator in the development, production and commercialization of #radiopharmaceuticals used for #medicalimaging and #therapeutic applications, announced a corporate update highlighting progress across its key programs during the past twelve months and upcoming milestones.

NorthStar Medical Radioisotopes, Beloit, Wisconsin campus (Photo: Business Wire)

News | Radiopharmaceuticals and Tracers | April 16, 2021
April 16, 2021 — ...
CDC and FDA Call for Pause on Janssen COVID-19 Vaccine Due to Rare Blood Clots #COVID19 #Janssen
Feature | Coronavirus (COVID-19) | April 15, 2021 | By Dave Fornell
April 15, 2021 — The U.S.